Global anti-obesity drugs market set to grow to $6.3bn by 2023, according to Visiongain report.

Visiongain’ has launched a new pharma report: Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

For free sample pages on this report please click on:
https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/#download_sampe_div

The Global Anti-Obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MOA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

The lead analyst of the report commented “During the forecast period, the global market is driven by the raising prevalence of overweight and obesity population; increasing awareness about the disease; growing diagnosis & treatment rates; obesity being recognized as a disease, adoption of national and international level policies by various countries.

In the global market, challenges continue with huge healthcare budget constraints, weak late-stage promising pipeline, generic competition, unavailability of safer & effective treatments, and availability of alternate therapies.”

Leading companies featured in the report include o Eisai/Arena, GlaxoSmithKline (GSK), Novo Nordisk, Orexigen/Takeda, Roche, Teva, Vivus

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

For more Pharma reports please visit https://www.visiongain.com/industries/pharma/

Related reports:
• Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018
https://www.visiongain.com/report/pharma-leader-series-top-50-pharmaceutical-contract-manufacturing-organisations-cmos-market-2018/
• Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029
https://www.visiongain.com/report/pharma-leader-series-top-generic-drug-producers-market-forecast-2019-2029/
• Dermatological Drugs Market Forecast 2018-2028
https://www.visiongain.com/report/dermatological-drugs-market-forecast-2018-2028/
• Global Diabetes Drugs Market 2017-2027
https://www.visiongain.com/report/global-diabetes-drugs-market-2017-2027/

Visiongain is one of the fastest-growing and most innovative independent business intelligence providers in Europe.
Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many more sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original business intelligence to depend upon.
https://www.visiongain.com/

Suite 143, Airport House Purley Way, Croydon CR0 0XZ

This release was published on openPR.